Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Rucaparib in Platinum-Sensitive Relapsed Ovarian Cancer
2013-000517-20Phase 2Unknown
- Sponsor
- Clovis Oncology
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rucaparib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more, sponsored by Clovis Oncology. Primary endpoint: Progression-free survival (PFS) in HRD-defined subgroups. Status: unknown.
02
Drugs
rucaparib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)malignant peritoneal neoplasm
Beyond the preview
Go deeper on 2013-000517-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000517-20.